(HealthDay)—In men with low-risk and intermediate-risk prostate cancer, stereotactic body radiotherapy is associated with low rates of severe toxic events and high rates of biochemical control, according to a study published online Feb. 8 in JAMA Network Open.
* This article was originally published here
